



ASSOCIAZIONE  
ITALIANA  
DI CULTURE  
CELLULARI



SERVIZIO SANITARIO REGIONALE  
EMILIA - ROMAGNA  
Istituto Ortopedico Rizzoli di Bologna  
Istituto di Ricovero e Cura a Carattere Scientifico



# TARGETED PROTEIN DEGRADATION: *from biology to pharmacology*

4<sup>th</sup> June 2024  
**BOLOGNA**

**IRCCS Istituto Ortopedico Rizzoli**  
**Centro di Ricerca Codivilla-Putti**  
**Aula Marchetti**

Via di Barbiano 1/10 - Bologna

*Scientific Coordinators*  
**Dr. Katia Scotlandi**  
**Dr. Caterina Mancarella**  
*Laboratory of Experimental Oncology*  
**IRCCS Istituto Ortopedico Rizzoli**

# TARGETED PROTEIN DEGRADATION: *from biology to pharmacology*

## Conference Aims

Targeted protein degradation is an emerging therapeutic modality based on the use of small molecules called degraders with the potential to tackle “undruggable targets” that have historically been highly challenging to target with conventional small molecules. Application of targeted protein degradation embraces experimental procedures based on engineered systems for ligand-induced protein degradation, computational and medical chemists, and rational design of novel therapeutic approaches.

This meeting will attract the interest of both basic and translational researchers, offering the opportunity to dive into the biggest challenges in early discovery and preclinical stages of targeted protein degradation. Joining a small but multidisciplinary group of academic and pharma discovery scientists with specific expertise in drug development and experimental modeling, attendees will learn how to identify new targets, discover novel ligands, and move them from early discovery to potential drug candidate. Interaction with speakers is favored to generate discussion, foster collaboration and knowledge exchange in the field of protein degradation.

Looking forward for meeting you, we welcome you in the lively city of Bologna, with its blend of fascinating culture, history, and delicious traditional food.


Caterina Mancarella  
AICC CTS Member



Katia Scotlandi  
AICC Past President



Michele Caraglia  
AICC President





## GENERAL INFORMATION

### Conference Venue

**IRCCS Istituto Ortopedico Rizzoli**  
**Centro di Ricerca Codivilla-Putti**  
**Aula Marchetti**  
Via di Barbiano 1/10, Bologna

### Secretary AICC

**aicc.meeting@gmail.com**

### Registration (VAT included)

**Deadline: 28<sup>th</sup> May 2024**

### Meeting Registration fee: 75€

*Reason for payment (causale):*

*please, indicate “your surname, name, TPD meeting registration”*

### Active AICC Membership fee: 50€

*Reason for payment (causale):*

*please, indicate “your surname, name, 2024 AICC Membership”*



Please scan the QR code for meeting registration  
or use the following link:

<https://docs.google.com/forms/d/e/1FAIpQLSfWYKLgWvb3Hcp4sPmWWT8jWKcMHp0OnqZ5gR-irsbAnLIsQ/viewform?usp=sharing>

### Bank transfer to:

Associazione Italiana di Colture Cellulari  
IT97B0538703612000003002045  
BPER BANCA S.P.A.  
L'Aquila, agenzia 10,  
Via Campo di Pile, 67100 L'Aquila (AQ)

*Copy of the receipt must be sent to:*

**aicc.meeting@gmail.com**

## SCIENTIFIC PROGRAMME

**09.30** | *Registration*

**10.00** | OPENING CEREMONY  
Greetings from Authorities  
Greetings from AICC President

### OPENING LECTURE

*Chairs:* **Katia Scotlandi, Michele Caraglia**

**10.30** | Recruiting E3 ligases for targeted protein degradation: PROTACs, glues and everything in between.  
**Andrea Testa** (*Amphista Therapeutics, Cambridge, UK*)

**11.10** | *Coffee break*

### Session I

#### PRECLINICAL MODELING AND CHALLENGES

*Chairs:* **Chiara Riganti, Andrea Morandi**

**11.30** | Development of PROTAC targeting the RNA-binding protein IGF2BP3 in sarcoma.  
**Caterina Mancarella** (*IRCCS Istituto Ortopedico Rizzoli*)

**11.50** | Molecular chameleonism is an opportunity to discover new oral PROTAC drugs.  
**Giulia Caron** (*University of Turin*)

**12.10** | AIRC-IFOM Drug Discovery Platform and Experimental Therapeutics Program.  
**Ciro Mercurio** (*IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy*)

**12.25** | PROTAC 101: how to develop drugs for undruggable targets.  
**Giuseppe Mancuso** (*Promega Italia*)

**12.40** | *Discussion*

**13.00** | *Light Lunch and Networking*

## Session II

### TARGETED PROTEIN DEGRADATION AS THERAPEUTIC TOOL: PROMISES AND CHALLENGES

*Chairs: Nicla Lorito, Massimo Donadelli*

- 14.00** Targeting Cyclin D1 with Folding Interfering Degraders, from Laboratory Research to Preclinical Development.  
**Simone Lanfredini** (*Sibylla Biotech S.p.A.*)
- 14.20** Development of PROTACs: a new chemical modality for neurodegenerative and infectious diseases.  
**Maria Laura Bolognesi** (*University of Bologna*)
- 14.40** Degradation of CDK12/13/CCNK induces a vulnerability in some cancers.  
**Frank Westermann** (*German Cancer Research Center, Heidelberg, Germany*)
- 15.00** “From Bench to Bedside - an Izon Science Approach” and “Holotomography and its X-tra way of doing live label-free imaging”.  
**Maira Bacchiega** (*Schaefer SEE Srl*)
- 15.20** *Discussion*
- 15.40** *Coffee break*

## CLOSING LECTURE

*Chairs: Joanna Kopecka, Enrico De Smaele*

- 16.00** Challenges in the development of PROTAC  
**Gabriele Cruciani** (*University of Perugia*)
- 16.30** *General Discussion and Closing Remarks*
- 16.45** *AICC General Assembly*

## **Scientific Coordinators**

*IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy*

Katia SCOTLANDI

Caterina MANCARELLA

## **AICC Scientific Committee**

### *President*

Michele CARAGLIA

*University of Campania “L. Vanvitelli”, Naples, Italy*

### *Vice President*

Francesca ZAZZERONI

*University of L’Aquila, L’Aquila, Italy*

### *Board of Directors*

Chiara RIGANTI (*Secretary*)

*University of Turin, Turin, Italy*

Enrico DE SMAELE (*Treasurer*)

*La Sapienza University of Rome, Rome, Italy*

Massimo DONADELLI

*University of Verona, Verona Italy*

Maria Teresa DI MARTINO

*“Magna Graecia” University, Catanzaro, Italy*

Andrea MORANDI

*University of Florence, Florence, Italy*

Katia SCOTLANDI (*past President*)

*IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy*

## **Scientific Technical Committee**

Daria CAPECE

*University of L’Aquila, L’Aquila, Italy*

Simone DI FRANCO

*University of Palermo, Palermo, Italy*

Alessandra FIORE

*University of Verona, Verona, Italy*

Joanna KOPECKA

*University of Turin, Turin, Italy*

Caterina MANCARELLA

*IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy*

Nicla LORITO

*University of Florence, Florence, Italy*

Silvia ZAPPAVIGNA

*University of Campania "L. Vanvitelli", Naples, Italy*

Pasquale ZIZZA

*Regina Elena National Institute for Cancer Treatment and Research, Rome, Italy*

## **Organizing Local Committee**

*IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy*

Cristina FERRARI

Alessandra DE FEO

Evelin PELLEGRINI

Marianna CARRABOTTA

Lisa TORACCHIO

## **Faculty**

Andrea TESTA

*Amphista Therapeutics, Cambridge, UK*

Caterina MANCARELLA

*IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy*

Giulia CARON

*University of Turin, Italy*

Ciro MERCURIO

*IFOM ETS - The AIRC Institute of Molecular Oncology, Milan, Italy*

Giuseppe MANCUSO

*Promega Italia*

Simone LANFREDINI

*Sibylla Biotech S.p.A., Bresso, Italy*

Maria Laura BOLOGNESI

*University of Bologna, Italy*

Frank WESTERMANN

*German Cancer Research Center, Heidelberg, Germany*

Maira BACCHIEGA

*(Schaefer SEE Srl)*

Gabriele CRUCIANI

*University of Perugia, Italy*

***With the support of***

The Italian Ministry of Foreign Affairs and  
International Cooperation and the Italian Ministry of Health within the  
Executive Programme for Scientific and Technological Cooperation  
between Italy and USA for the years 2023-2025 (MAECI-2023-23683465)

***With the unrestricted support of***

